Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The largest international ... medicinal plants and therapeutic derivatives thereof has endorsed ... and researchers about the challenges of adulterated herb ... ) The Society for Medicinal ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... DIEGO, Jan. 3, 2012  Amylin Pharmaceuticals, Inc. (Nasdaq: ... Morgan Healthcare Conference in San Francisco on Monday, January 9, ... Daniel M. Bradbury, president and chief executive officer of ... presentation and break-out session will be webcast through the "Investors" ...
... Renowned biochemist Michael A. Marletta, PhD, assumed the post ... January 1, succeeding Richard A. Lerner, MD, who led ... (Photo:  http://photos.prnewswire.com/prnh/20120102/DC28698 ) "I,m excited ... knowledge in the biosciences and applying that knowledge to ...
... BioNeutral Group, Inc. (OTCBB: BONU), a specialty life ... received $400,000 in connection with the Preferred Stock ... ("Vinfluence"), New South Wales, Australia.  Pursuant to the ... initial closing and a second funding of $200,000, ...
Cached Biology Technology:Michael A. Marletta Takes Office as New President of Scripps Research Institute 2BioNeutral Group Receives $400,000 in Equity Financing 2BioNeutral Group Receives $400,000 in Equity Financing 3
(Date:4/23/2014)... who have had a stroke, often suffer motor deficits ... study conducted in Taiwan, that will be published in ... is currently freely available on-line as an unedited early ... one group of stroke victims had their own peripheral ... and a similar group did not, those who received ...
(Date:4/23/2014)... the energy landscape in the U.S., but in ... the energy industry, residents and agricultural interests over ... degraded water quality is a potential risk unless ... in the ACS journal Environmental Science & ... point out that a major criticism of extracting ...
(Date:4/23/2014)... Climate fiction, or simply cli-fi, is a newly coined term ... global warming. New research from University of Copenhagen shows how ... to simulate the potential consequences of climate change and imagine ... than scientific data on changes in the atmosphere; it is ... by the books we read and the films we see. ...
Breaking Biology News(10 mins):Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3
... as calcified, inert structures, but researchers at Columbia University ... important novel function of the skeleton. Theyve shown for ... organ that helps control our sugar metabolism and weight ... development of type 2 diabetes. The research, ...
... passed on from mother to child is decided very early ... ovary. In a cell division process that is unique to ... egg before it is fertilised. Using a powerful microscope, researchers ... how the molecular machinery functions that is responsible for chromosome ...
... Haven, Conn. It is not just whats in your genes, ... between species at least in yeast according to a ... Weve known for a while that the protein coding genes of ... author Michael Snyder , the Cullman Professor of Molecular ...
Cached Biology News:Research shows skeleton to be endocrine organ 2A unique arrangement for egg cell division 2Evolution is driven by gene regulation 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... was first identified as the cellular homolog of ... and Jun D have been shown to be ... which are involved in dimerization and DNA binding, ... transcriptional activation, diverge. Antigen: ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
... (IC) Fixation Buffer, used in conjunction ... 00-8333), can be used to fix ... intracellular staining of cytokines and other ... have been specially formulated for reducing ...
Biology Products: